Pharsight

1. List of Sovaldi drug patents

Application	Filing Date	Opposition Party	Legal Status
EP12768967A	2018-08-22	Gillard, Richard Edward	Patent maintained as amended
EP08732818A	2015-02-23	Intellectual Property Services (IPS)	Granted and Under Opposition
EP08732818A	2015-02-23	STADA Arzneimittel AG	Granted and Under Opposition
EP08732818A	2015-02-23	ZBM Patents - Zea, Barlocci & Markvardsen	Granted and Under Opposition
EP08732818A	2015-02-23	Actavis Group PTC ehf	Granted and Under Opposition
EP08732818A	2015-02-20	Pharmaceutical Works POLPHARMA	Granted and Under Opposition
EP08732818A	2015-02-20	Generics [UK] Ltd (trading as Mylan)	Granted and Under Opposition
EP08732818A	2015-02-20	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP08732818A	2015-02-19	Fleischer, Holm Herbert	Granted and Under Opposition
EP08732818A	2015-02-19	ELLIS IP LTD	Granted and Under Opposition
EP08732818A	2015-02-10	MEDECINS DU MONDE	Granted and Under Opposition

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8889159	December, 2017	Terminated-Denied	Gilead Pharmasset LLC	Initiative for Medicines, Access & Knowledge (I-MAK), Inc.
US9284342	November, 2017	Terminated-Denied	Gilead Pharmasset LLC	Initiative for Medicines, Access & Knowledge (I-MAK), Inc.
US8633309	October, 2017	Terminated-Denied	Gilead Pharmasset LLC	Initiative for Medicines, Access & Knowledge (I-MAK), Inc.
US8334270	October, 2017	Terminated-Denied	Gilead Pharmasset LLC	Initiative for Medicines, Access & Knowledge (I-MAK), Inc.
US7964580	October, 2017	Terminated-Denied	Gilead Pharmasset LLC	Initiative for Medicines, Access & Knowledge (I-MAK), Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765	GILEAD SCIENCES INC	NA	Mar, 2028 (4 years from now)
US8334270	GILEAD SCIENCES INC	NA	Mar, 2028 (4 years from now)
US9085573	GILEAD SCIENCES INC	NA	Mar, 2028 (4 years from now)
US7964580	GILEAD SCIENCES INC	NA	Mar, 2029 (5 years from now)
US8633309	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2029 (5 years from now)
US9284342	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2030 (7 years from now)
US8618076	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Dec, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334270 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2028 (5 years from now)
US8580765 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2028 (5 years from now)
US9085573 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2028 (5 years from now)
US8889159	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (5 years from now)
US9549941	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (5 years from now)
US9549941 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (6 years from now)
US8633309 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2029 (6 years from now)
US8889159 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (6 years from now)
US7964580 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2029 (6 years from now)
US9284342 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2031 (7 years from now)
US8618076 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Jun, 2031 (8 years from now)

Do you want to check out SOVALDI patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 28, 2026
ODE* (ODE*)	Apr 7, 2024
Pediatric Exclusivity (PED)	Oct 7, 2024

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin

Dosage: PELLETS;ORAL